




1078–5884/00Detection of Abdominal Aortic Aneurysm in Patients with
Peripheral Artery Disease
A. Barba,* L. Estallo, L. Rodrı´guez, M. Baquer and M. Vega de Ce´nigaDepartment of Angiology and Vascular Surgery, Hospital de Galdakao, Bizkaia, SpainObjective. To describe the prevalence of abdominal aortic aneurysms (AAA) in patients with peripheral artery disease (PAD).
Design. Observational, descriptive, transverse study.
Patients and methods. We performed an abdominal ultrasound in 1190 consecutive patients with lower limb chronic
ischemia (1/99–12/04). We registered cardiovascular risk factors and clinical data for analysis.
Results. The ultrasound was inconclusive in 24 (2%) patients; 1166 patients completed the study. They were mostly male
(93.7%), with an age mean of 67G9.9 years (37.7–93.4). The main cardiovascular risk factors were: smoking (80.9%),
hypertension (41.7%) and hypercholesterolemia (31.4%). The prevalence of AAA was 13% (nZ151). Only 1.5% (nZ17) of
the patients had a large AAA (O5 cm). The AAA was clearly more prevalent in men (nZ148; 13.6%) than in women (nZ
3; 4.1%) (RR 3.47; 95% CI 1.11–10.89; pZ0.02). The prevalence significantly increased with age, with a maximum of
17.1% in over 75-year-old men (pZ0.006). Patients with tibial disease had a significantly higher prevalence of AAA than
aortoiliac or femoro-popliteal disease (pZ0.02).
Conclusions. The prevalence of AAA in patients with PAD is much higher than that reported in the general population. We
recommend that an abdominal ultrasound be routinely included in the study of these patients. Over 75-year-old men are at
particularly high-risk.Keywords: Abdominal aortic aneurysm; Peripheral artery disease; Screening.Introduction
Peripheral artery disease (PAD) affects 8–10 million
people in the USA. It is estimated that about 20% of the
population over 70-years-old suffer from some degree
of PAD.1 Abdominal aortic aneurysms (AAA) are a
frequent cause of death amongst adult males.2 They
account for about 9000 deaths in the USA annually,
most of them occurring in men over 65 years of age.3
AAA has been reported as the cause of death in about
2% of males over 60-years-old in Europe.4,5 If the AAA
are left undiagnosed and untreated one third will
eventually rupture.3,6 Early detection of these aneur-
ysms is of the utmost importance. Elective surgical
repair, with its low perioperative morbidity and
mortality (under 3% in most published series7,8)
would prevent the serious consequences of their
rupture, whose global mortality can be as high
as 90%.9
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AAA and of age-standardized mortality has increaseding author. Dr A. Barba, Department of Angiology and
ery, Hospital de Galdakao, Barrio Labeaga S/N, 48960
zkaia, Spain.
: abarba@hgda.osakidetza.net
0504 + 05 $35.00/0 q 2005 Elsevier Ltd. All rights reserin several countries during the last few years,6
possibly due to the rising life expectancy and to the
development of easy and low-cost diagnostic tools like
abdominal ultrasound. The prevalence varies depend-
ing on the population under study. Several recent
population-based studies have established the preva-
lence of AAA as 4–9% in men older than 60 years, and
0.5–3% in over 80-year-old women.3,5,10,11 In contrast,
patients suffering from PAD seem to be at particularly
high-risk for the development of AAA, with an overall
prevalence greater than 10%.12 The objective of this
study is to describe the prevalence and distribution of
AAA in patients with PAD in the 300,000 population
under our care.Patients and Methods
From January 1999 to December 2004 we set-up a
screening program for the detection of asymptomatic
AAA in which we performed an abdominal ultra-
sound on 1190 consecutive patients who first visited
our outpatient clinic and who were diagnosed with
PAD. We classified the patients according to their ageEur J Vasc Endovasc Surg 30, 504–508 (2005)
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We registered the usual cardiovascular risk factors
(tobacco use, hypertension, diabetes mellitus and
hypercholesterolemia), and other comorbidities
which could influence the development of an AAA
like: chronic obstructive pulmonary disease (COPD),
coronary artery disease (CAD), cerebrovascular
disease, chronic renal failure, cancer, or family history
of AAA.
We included both current and former smokers in
the category of ‘tobacco use’. Patients were regarded
as hypertensive when they were receiving treatment
(diet or medication) or their blood pressure was
registered above 140/90 twice in basal conditions.
We included complete blood tests in the study of all
our patients. We used the consensus criteria for the
diagnosis of diabetes mellitus (random blood glucose
R126 mg/dl) or the patients were already being
treated by an endocrinologist (diet, oral hypoglycae-
mics or insulin). We also used the standard criteria for
the diagnosis of hypercholesterolemia (total basal
cholesterol levels R200 mg/dl; LDL levels
R100 mg/dl) or the patients were receiving specific
medication or were under a supervised diet. COPD
was diagnosed when maximal voluntary ventilation
(MVV) was !80% or the patients were already under
treatment. We routinely performed a carotid duplex-
scan on all the patients. We considered that cerebro-
vascular disease was present when we detected an
asymptomatic significant (O50%) carotid stenosis or
the patient had a positive history of minor or major
stroke. We established the threshold for the presence of
chronic renal failure when serum creatinine levels
were R1.5 mg/dl. We registered the history of cancer
because recent studies suggest the development of
AAA are associated with serum TNF and C-reactive
protein levels, which are increased in neoplasic
processes.13–16.
PAD was diagnosed when the patient complained
of ischemic symptoms and had an ankle-brachial
index (ABI) !0.90. Pulse-volume recordings (PVR)
with spectral analysis and ABI were recorded on all
patients using a continuous, bidirectional Doppler,
VASOFLOW 2 of QUERMED with 7.5 and 8.5 MHz
transducers. We only performed a duplex-scan and/or
magnetic resonance angiography when the patient
suffered from incapacitating claudication or critical
ischemia. We classified the level of PAD as aortoiliac,
femoro-popliteal or tibial, depending on the location
of the lesions. Patients with combined levels of
ischemia were classified in the category of the most
proximal level of the disease (i.e. aortoiliacCfemoro-
popliteal disease was classified as aortoiliac;
femoro-poplitealCtibial disease was classified asfemoro-popliteal). We used Fontaine’s clinical cat-
egories of lower limb chronic ischemia: IIa—mild
claudication; IIb—incapacitating claudication; III—
rest pain; IV—tissue loss.
Using a SONOLINE SL-2 ultrasound (SIEMENS)
and a 3.5 Hz transducer, we measured the greatest
transverse and antero-posterior outer diameters of the
infrarenal abdominal aorta. All the scans were
performed by two radiologists with extensive experi-
ence in this field. We used the definition of AAA by
McGregor (R30 mm).3,17,18 The aortas were classified
in our study as normal (%26 mm), ectatic (27–29 mm)
and aneurysmatic (R30 mm). Patients diagnosed with
a !4 cm-diameter AAA were followed annually with
an abdominal ultrasound. Aneurysms of 4–4.9 cm
diameter were followed with a CT-scan every 6
months and AAA larger than 5 cm were electively
repaired when there was no anaesthetic
contraindication.
We performed a descriptive statistical analysis,
using the values meanGstandard deviations for
continuous variables and the number and percentage
of patients for categorical variables. We used the chi-
square test to compare nominal variables and inde-
pendent-samples t-test for continuous variables. The
patient information was entered into a Microsoft Excel
97 database and the statistical analysis was performed
using the SPSS 10.0 software (www.spss.com). We
accepted p!0.05 as significant.Results
The radiologists were unable to accurately measure
the aortic diameter in 24 (2%) of the 1190 ultrasounds
performed because of a hostile abdomen, excessive
bowel gas or obesity. The number of patients who
finally completed the study was 1166. It took a mean
time of 6G1.5 min to complete the diagnostic pro-
cedure. The mean aortic diameter of the 1166 patients
was 22.2G7.4 mm (11–74). Fig. 1 shows the distri-
bution of the aortic sizes. Almost 1000 (969; 83.1%)
aortas were normal with a mean diameter of 19.6G
3.2 mm (11–26), 46 (3.9%) were ectatic with a mean
diameter of 28.4G0.8 (27–29). We diagnosed 151 AAA
with a mean diameter of 37.4G8.3 mm (30–74),
equating to a prevalence of AAA in our patients
with PAD of 13%. Only 17 (1.5%) patients had a
R50 mm diameter (Table 1).
The patients studied were predominantly male (nZ
1093, 93.7%). AAA was clearly more prevalent in men
(nZ148; 13.6%) than in women (nZ3; 4.1%), with a
relative risk of 3.47 (95% CI 1.11–10.89, pZ0.02).
The mean age at diagnosis was 67G9.9 years (rangeEur J Vasc Endovasc Surg Vol 30, 11 2005
Fig. 2. Prevalence of AAA according to age groups.
Fig. 1. Distribution of aortic diameters.
A. Barba et al.50637.7–93.4). Men and women with a normal aorta had
an age mean of 66G9.8 years (37.7–93.4) and 71G10.3
years (40.3–90.2), respectively, while patients with an
AAA had an age mean of 69G8.4 years (46.3–89.4) and
81G3.3 years (77.6–84.4), respectively. The distribution
of patients and AAA by age and gender is detailed in
Table 2 and Fig. 2. The prevalence significantly
increases with the age of the patients (pZ0.006)
(Table 2). The main cardiovascular risk factors are
detailed in Table 3. Our patients with PAD and AAA
have a significantly higher prevalence of hypertension
(RR 1.85; 95% CI 1.31–2.62; p!0.0001), coronary artery
disease (RR 1.64; 95% CI 1.07–2.52; pZ0.023), carotid
artery disease (RR 1.82; 95% CI 1.18–2.79; pZ0.006),
COPD (RR 1.63; 95% CI 1.1–2.42; pZ0.015) and chronic
renal failure (RR 3.22; 95% CI 1.74–5.97; p!0.0001). In
contrast, the presence of diabetes mellitus was a
protective factor (RR 0.63; 95% CI 0.41–0.96; pZ
0.031). Smoking, hypercholesterolemia and a history
of neoplasia had no association with the diagnosis of
an AAA.
The commonest site of PAD was the femoro-
popliteal segment (58.2%). However, patients with
tibial disease had the highest prevalence of AAA
(19%), significantly higher than patients with aorto-
iliac (12.9%) and femoro-popliteal (11.3%) disease (pZ
0.02) (Table 4). 93.4% (nZ1 089) of the patients suffered
from intermittent claudication (grades IIa and IIb), and
12.9% (nZ140) of them were diagnosed with an AAA.
The patients suffering from critical ischemia (grades IIITable 1. Aortic diameters
Definition (mm) Total %
Normal aorta %26 969 83.1
Ectatic aorta 27–29 46 3.9




AAA, abdominal aortic aneurysm.
Eur J Vasc Endovasc Surg Vol 30, 11 2005and IV), 6.6% (nZ77) of the patients in this study, had
a prevalence of AAA of 14.3% (nZ11). The difference
is not significant (pZ0.43) (Table 5).Discussion
The time required to complete an abdominal ultra-
sound and measure the infrarenal aortic diameter by
qualified personnel is less than 10 min.19 It is an
accurate and reliable test, a simple and safe procedure
in almost every patient, with a sensitivity and
specificity in the detection of AAA of 95 and 100%,
respectively.3 Abdominal ultrasound is at present the
most practical screening method for infrarenal AAA.20
There is recent evidence that screening for AAA in the
general population is worthwhile. Fleming reported
that an invitation to screening was associated with a
43% reduction in AAA-related mortality in 65–75-
year-old men.3 Kim reported a reduction in AAA-
related deaths by 42%,21 and Wilmink reported a
reduction in the incidence of ruptured AAA by 64%.4
Implementation of a mass-screening program for
AAA increased the life expectancy according to the
Markov model in men over 60 years of age.5 Early
detection allows follow-up and reduces AAA-related
mortality. The diagnosis of small AAA does not
convey greater anxiety levels in the patients.3 The
introduction of a screening program would be
expected to reduce the number of emergency oper-
ations by identifying patients with AAA before
rupture and enabling elective surgery with lower
risk of postoperative death. The number of elective
operations is bound to increase initially and gradually
stabilise.22 Elective surgery conveys low mortality of
2–3% in most centers. The benefit of such a screening
program is clear in our hospital.
According to Wilmink, screening for asymptomatic
AAA can be cost-effective in populations with an
incidence of ruptured AAA of O5/10,000 person-
years.4 The MASS study reported that the cost-
effectiveness of screening for AAA in the general
population of men aged 65–74 years is, even at 4 years,
Table 2. Distribution of AAA by age and gender (statistical analysis: chi-square)
Age Total Gender AAA Prevalence p
!55 years 148 mZ142 8 5.4% 0.006
fZ6 – –
55–64 years 317 mZ309 35 11.0%
fZ8 – –
65–74 years 439 mZ409 65 14.8%
fZ30 – –
R75 years 262 mZ233 40 17.2%
fZ29 3 10.3%
AAA, abdominal aortic aneurysm; m, male; f, female.
Table 4. Prevalence of AAA according to location of PAD
(statistical analysis: chi-square)
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NHS thresholds, and it will improve substantially over
a longer period.17 The same and other authors have
sustained that the cost-effectiveness of screening for
AAA compares favourably with screening programs
for other pathologies: the cost per life-year gained by
screening for AAA is one third of the published cost
per life-year gained by breast cancer or colorectal
cancer screening and one eighth the cost for cervical
cancer screening.4,6 To save one life the number of
persons required to be screened for AAA is one tenth
of those needed to be screened for breast cancer.4,5,17
Screening for AAA appears worthwhile. The
question is how to initiate it. If screening in the general
population of older men seems to be beneficial in
reducing AAA-related mortality and also cost-effec-
tive, this must be even more significant in a subgroup
with a higher prevalence of AAA, such as patients
with PAD whose prevalence of AAA is about twice
that of the general population. Most AAA in our study
(88.7%) have been detected when they were still small
(107 AAA 30–39 mm, 27 AAA 40–49 mm), allowing for
follow-up, surveillance and elective repair if they
reach a R5 cm diameter.
The strong association of AAA with age has been
well established both for men and women. The
prevalence of AAA increases with age, with a







Tobacco use 819 (80.7%) 124 (82.1%) 0.68
HTA 403 (39.7%) 83 (55%) !0.0001
Hypercholesterolemia 326 (32.1%) 40 (26.5%) 0.16
Diabetes mellitus 279 (27.5%) 29(19.2%) 0.031
CAD 143 (14.1%) 32 (21.2%) 0.023
Carotid artery disease 131 (12.9%) 32 (21.2%) 0.006
COPD 184 (18.1%) 40 (26.5%) 0.015
CRF 36 (3.5%) 16 (10.6%) !0.0001
Neoplasia 56 (5.5%) 11 (7.3%) 0.38
AAA, abdominal aortic aneurysm; n, number; HTA, arterial
hypertension; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; CRF, chronic renal failure.young (!55 years) male patients was 5.4%, over 10%
in men in their fifties, almost 15% in the sixth decade,
and over 17% in men over 75-years-old. AAA are
much less prevalent in women and occur about 10
years later in life compared to men. We found no AAA
in under 75-year-old women suffering from PAD.
However, even though the subgroup of women over
75 years of age was small in our study (nZ29), their
prevalence of AAA was as high as 10.3%. These results
do not justify the routine performance of an abdominal
ultrasound in younger women with PAD. The screen-
ing program should only be performed in women in
their seventies with PAD or associated risk factors. In
the next few decades the distribution of cardiovascular
risk factors and secondary cardiovascular diseases
amongst women is likely to change significantly. New
epidemiological studies will be essential in 30–40 years
and the present recommendations will probably have
to be revised.
We have demonstrated a strong association
between the presence of AAA and chronic renal
failure in patients with PAD. AAA was also positively
associated with hypertension, coronary artery disease,
carotid artery disease and COPD, and negatively
associated with diabetes mellitus. A more detailed
multivariate analysis is required to be able to drawTotal No. AAA AAA p
Aorto-iliac 303 (25.9%) 264 (87.1%) 39 (12.9%)
Femoro-popliteal 679 (58.2%) 602 (88.7%) 77 (11.3%) 0.02
Tibial 184 (15.8%) 149 (81.0%) 35 (19.0%)
AAA, abdominal aortic aneurysm.
Table 5. Prevalence of AAA according to degree of ischemia
(statistical analysis: chi-square)
Total No. AAA AAA p
IIa 836 (71.7%) 720 (86.1%) 116 (13.9%) 0.43
IIb 253 (21.7%) 228 (90.1%) 25 (9.9%)
III 61 (5.2%) 52 (85.2%) 9 (14.8%)
IV 16 (1.4%) 14 (87.5%) 2 (12.5%)
AAA, abdominal aortic aneurysm.
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A. Barba et al.508reliable conclusions on this issue. A systematic review
of population-based screening studies has shown a
moderate association of PAD with AAA (OR 2.5).6,23
Brivady et al.24 noted an association between AAA and
aortoiliac occlusive disease and Galland12 reported a
higher association with femoro-popliteal disease. In
our study, patients with tibial disease showed the
highest prevalence of AAA. We do not have an
explanation for this finding. We found no association
between the degree of lower limb ischemia and the
presence of AAA, similar to other authors.24
Cost-effectiveness of a screening program can be
increased if the screening is specifically targeted at a
high-risk group. With the data obtained in our study,
we can conclude that patients with PAD have a
significantly higher prevalence of AAA than the
general population, so they can be considered a
high-risk group for the development of AAA. We
believe it is necessary to perform an abdominal
ultrasound in all male patients with PAD for the
screening of AAA. Screening for AAA in women is, at
the present time, more debatable, but we suggest
introducing the program in older women with PAD.References
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